
377: Melodrama at the FDA and the Pfizer-Novo bidding war
The Readout Loud
00:00
Why is MetSera so desirable despite many obesity startups?
Elaine explains MetSera's monthly-dosed GLP-1/amylin assets, lack of published competitive data, and Pfizer's need for market entry.
Play episode from 24:00
Transcript


